Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

This study has been terminated.
(Modified dose schedule presented no advantage over previously studied schedule)
Information provided by:
Cylene Pharmaceuticals Identifier:
First received: August 7, 2009
Last updated: NA
Last verified: August 2009
History: No changes posted
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2008
  Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)